Cases & Deals

AbbVie invests in Avaxia Biologics

Clients AbbVie Inc.

Jones Day advised AbbVie Inc., a leading pharmaceutical research and development company, in connection with its purchase of Series B Preferred Stock in a private placement by Avaxia Biologics, Inc., a clinical-stage biotechnology company focused on the development of orally-delivered antibody therapeutics.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.